

## Treatment Response of Chronic Myelogenous Leukemia in Dr. Soetomo Hospital

### Abstrak :

*Chronic myelogenous leukemia is the most frequent hematology malignancies in adult. In the US, the frequency of CML is about 15% of all hematological malignancies. The incidence was 1-2 : 100.000, with male and female 1.3 : 1, and it increases associated with age 45-55 year. In Internal Medicine Department, Airlangga University School of Medicine, Dr. Soertomo Hospital, Surabaya, CML is the most frequent hematological malignancy after malignant lymphoma. The diagnosis was established by clinical festures such as organomegaly, leukocytosis and bone marrow aspiration. CML treatment includes supportive therapy, chemoteraphy, and stem cell transplantation. The cheaper and frequently used chemotherapy are busulfan and hydroxyurea, but the response is not satisfying. In CML patient with positive Philadelphia chromosome, treatment with imatinib gives response rate about 90-95%. The purpose of this study was to find out the response of hyrea, busulfan and imatinib therapy on CML. Sample of this study was the patient in Medical Oncology and Hematology Outpatient Clinic of Dr. Soetomo Hospital, from January 1, 2004, to December, 31, 2006. Along this time there were 58 patients with CML. Twenty eight patients were females and the rests were male. The response of patient with myeleran showed that three patients had complete remission. Among those receiving hydroxyurea 6,6 % showed partial remision, and 79.9% patients showed complete remission treatment by imatinib.*

### Keyword :

*hematology malignancies, chronic myelogenous leukemia, hyrea, busulfan, imatinib, Dr Soetomo Hospital*

### Daftar Pustaka :

*Druker, BJ, Guilhot, F, Oâ€™Brien, SG Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia N Engl J of Med 2006 -  
Faderl, S, Talpaz, M, Estrov, Z, Kantarjian, HM Chronic myelogenous leukemia: Biology and therapy Annals of Internal Medicine 1999 -*